The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
本发明涉及公式(Ia)中的某些(1,
2,4-噁二唑-3-基)-1,2,3,4-四
氢环-五
氢-
苯并[b]
吲哚-3-基
羧酸衍
生物及其药学上可接受的盐,该衍
生物具有有用的药理特性,例如作为S1P1受体的激动剂。本发明还提供了含有所述化合物的药物组合物,以及使用所述化合物和组合物治疗S1P1相关疾病的方法,例如
银屑病、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、I型糖尿病、痤疮、微
生物感染或疾病以及病毒感染或疾病。